Dalton Receives Funding for Development of RSV and Parainfluenza Type 3 Vaccines

December 1, 2014
BioPharm International Editors

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

Dalton Pharma Services announced on Nov. 25, 2015 that it was awarded funding from International Science and Technology Partnerships Canada (ISTPCanada), a company specializing in R&D collaboration programs, as part of the 2013 Canada–China Joint Initiative on Human Vaccine Research and Development.

The project’s goal is to complete the pre-clinical development of the first vaccine for respiratory syncytial virus, parainfluenza type 3 virus, and a co-formulated combination vaccine. The project uses novel adjuvant designed to induce a powerful balanced immune response against a variety of viral and bacterial antigens.

Academic and industrial vaccine development leaders make up the team, including the Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO–InterVac), the Pan-Provincial Vaccine Enterprise Inc. (PREVENT), the South China United Vaccine Institute, and the Guangzhou Institute of Respiratory Disease. Additional funding was awarded to VIDO–InterVac through Canadian Institutes of Health Research and the Chinese partners through the Chinese Ministry of Science and Technology.

Source: Dalton Pharma Services